Eli Lilly’s Metabolic Medicine Takes the Lead in the Race to Develop an Oral GLP-1 Drug
The next wave of metabolic medicines in development includes oral GLP-1 drugs that work comparably to currently available injectable medicines, ...
The next wave of metabolic medicines in development includes oral GLP-1 drugs that work comparably to currently available injectable medicines, ...
Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the ...
Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its ...
The Food and Drug Administration on Friday cleared Eli Lilly’s obesity drug Zepbound as the first treatment for a common ...
The battle for market share between the two leaders in the booming obesity drug sector has a new data point ...
Highly anticipated Phase 2 data for Amgen’s obesity drug show that on average, participants lost about 20% of their weight ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Good morning. As a treat for Labor Day weekend, we’re running a deal for STAT+ subscriptions. If you use the ...
The longest clinical trial to date for a blockbuster Eli Lilly metabolic disorder drug now has data showing the treatment ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.